{"denomUnitsSelected":"Participants","description":"PFS was defined as time from randomization to progression or death, whichever occurred first. Progression is characterized by any of the following:\n\n* ≥ 50% increase from nadir since start of treatment (tx) in the sum of the products of ≥2 lymph nodes on 2 consecutive examinations 2 weeks apart\n* ≥ 50% increase from nadir since start of tx in the size of liver and/or spleen\n* ≥ 50% increase in the absolute number of circulating lymphocytes not due to tumor flare reaction. The absolute lymphocyte count must be ≥ 5x10\\^9/L to qualify as progression.\n* Transformation to a more aggressive histology. For patients who achieve a complete response or nodular partial response, progression is defined as recurrence of circulating leukemia cell clone in the peripheral blood and an absolute lymphocyte count \\> 5x10\\^9/L and/or recurrence of palpable lymphadenopathy \\> 1.5 cm by physical exam.\n\nThe distribution of PFS by SNPs will be reported.","reportingStatus":"NOT_POSTED","timeFrame":"Assessed every 3 months until progression; after progression, assessed every 3 months for first 2 years, every 6 months for years 3-5","title":"Association Between Single Nucleotide Polymorphisms (SNPs) and PFS","type":"OTHER_PRE_SPECIFIED"}